Recent advances in tumor-targeting chemotherapy drugs.
作者信息
Ojima Iwao
机构信息
Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY 11794-3400, USA.
出版信息
Cancer Drug Resist. 2021;4(4):885-887. doi: 10.20517/cdr.2021.86. Epub 2021 Sep 8.
Abstract
摘要
相似文献
1
Recent advances in tumor-targeting chemotherapy drugs.肿瘤靶向化疗药物的最新进展。
Cancer Drug Resist. 2021;4(4):885-887. doi: 10.20517/cdr.2021.86. Epub 2021 Sep 8.
2
Recent advances in drug delivery systems for targeting brain tumors.靶向脑肿瘤的药物传递系统的最新进展。
Drug Deliv. 2023 Dec;30(1):1-18. doi: 10.1080/10717544.2022.2154409.
3
Recent advances in active targeting of nanomaterials for anticancer drug delivery.近年来，纳米材料用于抗癌药物输送的主动靶向技术取得了进展。
Adv Colloid Interface Sci. 2021 Oct;296:102509. doi: 10.1016/j.cis.2021.102509. Epub 2021 Aug 18.
4
Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.基于智能纳米药物的靶向肿瘤化疗的最新进展。
Small. 2018 Nov;14(45):e1802417. doi: 10.1002/smll.201802417. Epub 2018 Sep 3.
5
[Advances in study of macrophages in chemotherapy resistance of cancer].[巨噬细胞在癌症化疗耐药性中的研究进展]
Yao Xue Xue Bao. 2016 Oct;51(10):1513-9.
6
Recent Advances in Targeting Tumor Energy Metabolism with Tumor Acidosis as a Biomarker of Drug Efficacy.以肿瘤酸中毒作为药物疗效生物标志物靶向肿瘤能量代谢的最新进展
J Cancer Sci Ther. 2016;8(1):20-29. doi: 10.4172/1948-5956.1000382.
7
Recent advances in tumor vasculature targeting using liposomal drug delivery systems.近年来，利用脂质体药物递送系统靶向肿瘤血管的研究进展。
Expert Opin Drug Deliv. 2009 Dec;6(12):1297-309. doi: 10.1517/17425240903289928.
8
Recent advances in aptamer-based therapeutic strategies for targeting cancer stem cells.基于适配体的癌症干细胞靶向治疗策略的最新进展。
Mater Today Bio. 2023 Mar 11;19:100605. doi: 10.1016/j.mtbio.2023.100605. eCollection 2023 Apr.
9
Advances in silica based nanoparticles for targeted cancer therapy.用于靶向癌症治疗的二氧化硅基纳米颗粒的研究进展。
Nanomedicine. 2016 Feb;12(2):317-32. doi: 10.1016/j.nano.2015.10.018. Epub 2015 Dec 17.
10
Recent Advances in Engineering of Lipid Drug Conjugates for Cancer Therapy.用于癌症治疗的脂质药物偶联物工程的最新进展。
ACS Biomater Sci Eng. 2019 Sep 9;5(9):4148-4166. doi: 10.1021/acsbiomaterials.9b00689. Epub 2019 Jul 18.
本文引用的文献
1
Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene ()-mutations in first-line for advanced non-small cell lung cancer.奥希替尼用于一线治疗晚期非小细胞肺癌中激活表皮生长因子受体基因（）突变的成本效益分析
Cancer Drug Resist. 2021 Apr 27;4(3):740-744. doi: 10.20517/cdr.2021.14. eCollection 2021.
2
Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells .胸苷介导的保护性自噬使结肠癌细胞对雷帕霉素产生抗性。
Cancer Drug Resist. 2021 May 24;4(3):719-727. doi: 10.20517/cdr.2021.21. eCollection 2021.
3
Emerging RAS-directed therapies for cancer.新兴的针对癌症的RAS靶向疗法。
Cancer Drug Resist. 2021 Apr 8;4(3):543-558. doi: 10.20517/cdr.2021.07. eCollection 2021.
4
Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging.通过荧光共振能量转移成像评估含前列腺特异性膜抗原（PSMA）的内体的还原电位。
Cancer Drug Resist. 2021 Mar 19;4(1):223-232. doi: 10.20517/cdr.2020.84. eCollection 2021.
5
Advances in preclinical evaluation of experimental antibody-drug conjugates.实验性抗体药物偶联物的临床前评估进展
Cancer Drug Resist. 2021;4(4):745-754. doi: 10.20517/cdr.2021.37. Epub 2021 Jul 4.
Zotero 插件